Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide

被引：13
|
作者：
Kapitza, Christoph [1 ]
Zdravkovic, Milan [2 ]
Zijlstra, Eric [1 ]
Segel, Stine [2 ]
Heise, Tim [1 ]
Flint, Anne [2 ]
机构：
[1] Profil Inst Stoffwechselforsch GmbH, D-41460 Neuss, Germany
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 06期
关键词：
Type 2 diabetes mellitus; glucagon-like peptide-1; incretin; exenatide; DPP-IV; GLUCAGON-LIKE PEPTIDE-1; ABSORPTION; INSULIN; NN2211; CELL; PHARMACODYNAMICS; TOLERABILITY; SAFETY;
D O I：
10.1177/0091270010374474
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：951 / 955
页数：5
相关论文
共 50 条
  • [31] Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes
    Matthews, David
    Marre, Michel
    Le-Thl, T. U. Duyen
    Zdravkovic, Milan
    Simo, Rafael
    DIABETES, 2008, 57 : A150 - A151
  • [32] The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
    Lykkegaard, Kirsten
    Larsen, Philip J.
    Vrang, Niels
    Bock, Camilla
    Bock, Troels
    Knudsen, Lotte Bjerre
    SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) : 94 - 103
  • [33] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [34] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    Aimaretti, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (08) : 701 - 703
  • [35] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    G. Aimaretti
    Journal of Endocrinological Investigation, 2009, 32 : 701 - 703
  • [36] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
  • [37] Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes
    Garber, A.
    Henry, R.
    Ratner, R.
    Garcia-Hernandez, P.
    Pattzi, H. M. Rodriguez
    Olvera-Alvarez, I.
    Hale, P. M.
    Zdravkovic, M.
    Bode, B.
    DIABETOLOGIA, 2008, 51 : S358 - S359
  • [38] Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial
    Finer, N.
    Al Hakim, M.
    Astrup, A.
    Harper, A.
    Lean, M.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Van Gaal, L.
    DIABETOLOGIA, 2009, 52 : S11 - S12
  • [39] The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
    Flint, A.
    Kapitza, C.
    Zdravkovic, M.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 958 - 962
  • [40] In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss
    Fonseca, V. A.
    Henry, R. R.
    Tabanera y Palacios, R.
    Brett, J.
    Plutzky, J.
    DIABETOLOGIA, 2010, 53
12345